# CYFIP2 Polyclonal Antibody

| | |
|---|---|
| **Catalog No** | YP-Ab-10599 |
| **Isotype** | IgG |
| **Reactivity** | Human;Mouse;Rat |
| **Applications** | WB;ELISA |
| **Gene Name** | CYFIP2 |
| **Protein Name** | CYFIP2 |
| **Immunogen** | Synthesized peptide derived from CYFIP2 at AA range: 1171-1220 |
| **Specificity** | CYFIP2 Polyclonal Antibody detects endogenous levels of CYFIP2 |
| **Formulation** | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| **Source** | Polyclonal, Rabbit,IgG |
| **Purification** | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| **Dilution** | WB 1:500-2000, ELISA 1:10000-20000 |
| **Concentration** | 1 mg/ml |
| **Purity** | ≥90% |
| **Storage Stability** | -20°C/1 year |
| **Synonyms** | Cytoplasmic FMR1-interacting protein 2 (p53-inducible protein 121) |
| **Observed Band** | 150+45kD |
| **Cell Pathway** | Cytoplasm . Nucleus . Cytoplasm, perinuclear region . Cell junction, synapse, synaptosome . Highly expressed in the perinuclear regionand enriched in synaptosomes (By similarity). Treatment with leptomycin-B triggers translocation to the nucleus (PubMed:17245118). . |
| **Tissue Specificity** | Expressed in T-cells. Increased expression is observed in CD4(+) T-lymphocytes from patients with multiple sclerosis (at protein level). |
| **Function** | disease:Up-regulated significantly in CD4+ T lymphocytes from patients with multiple sclerosis (at protein level).,function:Involved in T-cell adhesion and p53-dependent induction of apoptosis. Does not bind RNA.,induction:By p53.,RNA editing:Partially edited. Editing appears to be brain-specific.,similarity:Belongs to the CYFIP family.,subcellular location:Highly expressed in the perinuclear region. Enriched in synaptosomes. Treatment with leptomycin-B triggers translocation to the nucleus.,subunit:Interacts with FMR1, FXR1 AND FXR2. Component of the WAVE1 complex composed of ABI2, CYFIP2, C3orf10/HSPC300, NCKAP1 and WASF1/WAVE1. CYFIP2 binds to activated RAC1 which causes the complex to dissociate, releasing activated WASF1. The complex can also be activated by NCK1., |
| **Background** | disease:Up-regulated significantly in CD4+ T lymphocytes from patients with multiple sclerosis (at protein level).,function:Involved in T-cell adhesion and |

| | |
|---|---|
| | p53-dependent induction of apoptosis. Does not bind RNA.,induction:By p53.,RNA editing:Partially edited. Editing appears to be brain-specific.,similarity:Belongs to the CYFIP family.,subcellular location:Highly expressed in the perinuclear region. Enriched in synaptosomes. Treatment with leptomycin-B triggers translocation to the nucleus.,subunit:Interacts with FMR1, FXR1 AND FXR2. Component of the WAVE1 complex composed of ABI2, CYFIP2, C3orf10/HSPC300, NCKAP1 and WASF1/WAVE1. CYFIP2 binds to activated RAC1 which causes the complex to dissociate, releasing activated WASF1. The complex can also be activated by NCK1., |
| **matters needing attention** | Avoid repeated freezing and thawing! |
| **Usage suggestions** | This product can be used in immunological reaction related experiments. For more information, please consult technical personnel. |

# Products Images




Western Blot analysis of HEPG2 Hela cells using CYFIP2 Polyclonal Antibody diluted at 1:500. Secondary antibody(catalog#:RS0002) was diluted at 1:20000



Immunohistochemical analysis of paraffin-embedded human-tonsil, antibody was diluted at 1:200



Immunohistochemical analysis of paraffin-embedded human-tonsil, antibody was diluted at 1:200



Immunohistochemical analysis of paraffin-embedded human-colon, antibody was diluted at 1:200



Immunohistochemical analysis of paraffin-embedded human-colon, antibody was diluted at 1:200